.png)
.png)
.png)
.png)
HDL Resource Center
The Translation of HDL Science Curriculum Slide Library consists of 6 (six) interactive slide lecture note modules and 2 interactive case studies that convey the latest evidence and research on HDL and residual risk epidemiology, HDL metabolism, HDL functionality and subfractions, existing HDL raising therapies, novel targets of therapy and therapies in development. The HDL Slide Library provides slide presentation materials with state of the art, peer-reviewed content developed by International experts in lipidology and HDL research. These slides and case studies efficiently translate the core scientific principles of the HDL curriculum to clinical practice.
Chapter 1Epidemiology and Nomenclature
Peter P. Toth, MD, PhD, FNLA
Rachel H. Mackey, PhD, MPH
Richard H. Karas, MD, PhD
Certified for 1 AMA PRA Category 1 CreditTM
January 2013 - January 2014
This slide module will give an overview of the epidemiology of HDL, the history of HDL-C as a therapeutic target, how HDL-C is associated with CVD Outcomes and an overview of measures of HDL quantity.
Chapter 2HDL Metabolism, Cholesterol Efflux and Relationship to Atherosclerosis
Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA
H. Bryan Brewer, Jr., MD, FNLA
Robert A. Hegele, MD
Certified for 1 AMA PRA Category 1 CreditTM
February 2013 - February 2014
This slide module will discuss HDL metabolism from the macrophage to the intestines, genetic HDL deficiency disorders, measurements of HDL subfractions and function and the link between triglyceride and HDL metabolism.
Chapter 3HDL Functionality (Non-efflux functions) AND Relationships to Atherosclerosis
M. John Chapman, BSc, PhD, DSc
Anatol Kontush, BSc, PhD
Certified for 1 AMA PRA Category 1 CreditTM
December 2012 - December 2013
The functionality of HDL particles is intimately related to their structure and physicochemical properties, and notably to their lipidome and proteome.
Chapter 4Current Therapies to Target HDL - Update on Clinical Trials
Benjamin J. Ansell, MD, FNLA
Peter H. Jones, MD
Laurence S. Sperling, MD, FACC, FAHA, FACP
Certified for 1 AMA PRA Category 1 CreditTM
May 2013 - May 2014
This slide module will address the current therapies to target HDL through an update on clinical trials. In addition the an overview of how lifestyle changes can positively impact CVD outcomes will be presented.
Chapter 5CETP as a therapeutic Target
Phillip Barter, MD, PhD
John JP Kastelein, MD, PhD, FESC
Steve J. Nicholls, MBBS, PhD, FRACP
Certified for 1.5 AMA PRA Category 1 CreditTM
October 2012 - October 2013
CETP as a Therapeutic Target; History, Metabolism and Therapeutic Development; and CETP Inhibitors.
Chapter 6Non-CETP Novel Targets and New Drug Therapies Targeting HDL
Michael Davidson, MD, FNLA
Danielle Duffy, MD
Certified for 1 AMA PRA Category 1 CreditTM
December 2012 - December 2013
The module will present the differences amongst the various therapeutic options and demonstrate that the overarching goal of all novel HDL therapeutics is the prevention of cardiovascular events.
Case StudySuparna Visits 1 & 2
Robert S Rosenson, MD, FACC, FAHA, FACP, FNLA
Benjamin J Ansell, MD, FNLA
Certified for 1 AMA PRA Category 1 CreditTM
December 2012 - December 2013
Recognition of elevated cardiovascular risk in a patient typically overlooked for aggressive cardiovascular intervention will be reinforced during this case review.
Case StudyCertified for 1 AMA PRA Category 1 CreditTM
December 2012 - December 2013
Patient assessment and management of this challenging case during 2 sequential physician visits will be discussed.
Newsletter 1
The Association Between HDL Cholesterol and CVD Risk
Peter P. Toth, MD, PhD, FNLA
Robert D. Brook, MD
Certified for .5 AMA PRA Category 1 CreditTM
November 2012 - November 2013
The goal of this activity is to help clinicians successfully manage and treat residual risk in cardiovascular disease (CVD) due to abnormally low or dysfunctional HDL.
Newsletter 2
HDL and Atherogenesis
Peter P. Toth, MD, PhD, FNLA
Benjamin J. Ansell, MD FACC, FACP, FNLA
Certified for .5 AMA PRA Category 1 CreditTM
December 2012 - December 2013
The goal of this educational activity is to expand the ability of health care professionals to successfully manage and treat residual risk in cardiovascular disease (CVD) due to abnormally low or dysfunctional HDL.
Newsletter 3
Current and Emerging HDL-Targeted Therapies in Cholesterol Management
Peter P. Toth, MD, PhD, FNLA
Philip Barter, MD
Certified for .5 AMA PRA Category 1 CreditTM
December 2012 - December 2013
The goal of this educational activity is to expand the ability of health care professionals to successfully manage and treat residual risk in cardiovascular disease (CVD) due to abnormally low or dysfunctional HDL.
Newsletter 4
Certified for .25 AMA PRA Category 1 CreditTM
December 2013 - December 2014
The goal of this educational activity is to expand the ability of health care professionals to successfully manage and treat residual risk in cardiovascular disease (CVD) due to abnormally low or dysfunctional HDL.
Social